Scar - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 109 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Scar - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Scar - Pipeline Review, H2 2014', provides an overview of the Scar's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Scar, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Scar and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Scar
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Scar and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Scar products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Scar pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Scar
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Scar Overview 9
Therapeutics Development 10
Pipeline Products for Scar - Overview 10
Pipeline Products for Scar - Comparative Analysis 11
Scar - Therapeutics under Development by Companies 12
Scar - Therapeutics under Investigation by Universities/Institutes 14
Scar - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Scar - Products under Development by Companies 18
Scar - Products under Investigation by Universities/Institutes 19
Scar - Companies Involved in Therapeutics Development 20
3M Drug Delivery Systems 20
AlbireoPharma 21
Altacor Ltd. 22
Beech Tree Labs, Inc. 23
Biomolecular Therapeutics GmbH 24
BiOrion Technologies B.V. 25
Clanotech AB 26
Critical Outcome Technologies Inc. 27
Derma Sciences, Inc. 28
Easton Pharmaceuticals Inc. 29
Escape Therapeutics, Inc. 30
EyeGene, Inc. 31
Fibrocell Science, Inc. 32
FirstString Research, Inc. 33
Juventas Therapeutics, Inc. 34
Kasiak Research Pvt. Ltd. 35
Pergamum AB 36
Pfizer Inc. 37
RXi Pharmaceuticals Corporation 38
Sirnaomics, Inc. 39
Scar - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
A-3914 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
A-5425 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
azficel-T - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BMT-101 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BOT-191 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BTL-slo - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CLT-28643 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CM-101 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
coagulation factor XIVa (human) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
DSC-127 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
EGS-001 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
EP-003 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Evitar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
FibroStem - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Granexin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ICX-RHY - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JVS-100 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
nefopam hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PF-06473871 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PXL-01 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Refaglo - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RXI-109 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
S-34240 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules for CNS Scarring - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
STP-705 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
tranilast - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Scar - Recent Pipeline Updates 86
Scar - Dormant Projects 99
Scar - Discontinued Products 100
Scar - Product Development Milestones 101
Featured News & Press Releases 101
Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum 101
Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 101
Feb 03, 2014: RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference 101
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 102
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 103
Jul 15, 2013: FirstString Research, Inc. Announces the Achievement of Primary Endpoints in Three Phase 2 Clinical Trials of Granexin� Gel for the Treatment of Chronic Wounds and Scar Reduction 103
Jul 12, 2013: RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study 104
Jun 27, 2013: Pergamum Reports Positive Follow-up Data From Phase II Clinical Trial Of PXL-01 For Prevention Of Post-surgical Adhesions 105
Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 106
Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 107
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109

List of Tables
Number of Products under Development for Scar, H2 2014 10
Number of Products under Development for Scar - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Scar - Pipeline by 3M Drug Delivery Systems, H2 2014 20
Scar - Pipeline by AlbireoPharma, H2 2014 21
Scar - Pipeline by Altacor Ltd., H2 2014 22
Scar - Pipeline by Beech Tree Labs, Inc., H2 2014 23
Scar - Pipeline by Biomolecular Therapeutics GmbH, H2 2014 24
Scar - Pipeline by BiOrion Technologies B.V., H2 2014 25
Scar - Pipeline by Clanotech AB, H2 2014 26
Scar - Pipeline by Critical Outcome Technologies Inc., H2 2014 27
Scar - Pipeline by Derma Sciences, Inc., H2 2014 28
Scar - Pipeline by Easton Pharmaceuticals Inc., H2 2014 29
Scar - Pipeline by Escape Therapeutics, Inc., H2 2014 30
Scar - Pipeline by EyeGene, Inc., H2 2014 31
Scar - Pipeline by Fibrocell Science, Inc., H2 2014 32
Scar - Pipeline by FirstString Research, Inc., H2 2014 33
Scar - Pipeline by Juventas Therapeutics, Inc., H2 2014 34
Scar - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 35
Scar - Pipeline by Pergamum AB, H2 2014 36
Scar - Pipeline by Pfizer Inc., H2 2014 37
Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 38
Scar - Pipeline by Sirnaomics, Inc., H2 2014 39
Assessment by Monotherapy Products, H2 2014 40
Number of Products by Stage and Target, H2 2014 42
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 46
Number of Products by Stage and Molecule Type, H2 2014 48
Scar Therapeutics - Recent Pipeline Updates, H2 2014 86
Scar - Dormant Projects, H2 2014 99
Scar - Discontinued Products, H2 2014 100